Acute ischemic stroke (AIS) is a medical condition where blood supply to the brain is interrupted, depriving brain cells of oxygen and nutrients. If not treated promptly, it can cause permanent damage or even death. AIS treatment aims to restore blood circulation and minimize brain injury. Thrombolytic drugs like tissue plasminogen activator (tPA) are used to dissolve blood clots blocking arteries. Other products like mechanical thrombectomy devices help remove clots through minimally invasive surgeries. The increasing prevalence of stroke and lack of available treatments necessitate innovative solutions.

The global Acute Ischemic Stroke (AIS) Market is estimated to be valued at US$ 12 billion in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

The growing preference for minimally invasive endovascular treatments over conventional medications is a key trend fueling the AIS market growth. Endovascular thrombectomy procedures using stent retrievers and aspiration catheters have significantly higher recanalization rates compared to intravenous thrombolysis alone. Since endovascular treatments offer higher chances of complete or near-complete revascularization with a considerably lower risk of symptomatic intracranial hemorrhage, they are rapidly replacing intravenous thrombolysis as the standard of care for AIS patients. This shift towards endovascular solutions is expected to boost the demand for mechanical thrombectomy devices during the forecast period.

Segment Analysis

The global acute ischemic stroke (AIS) market is segmented based on treatment type, imaging technology, end-user and geography. Under the treatment type segment, thrombolysis drugs dominate currently due to their effectiveness in dissolving blood clots. This segment is further divided into tissue plasminogen activator, protease inhibitors, and others. Among them, tissue plasminogen activator holds the largest market share owing to being the first FDA-approved drug for AIS treatment.

Key Takeaways

The Global Acute Ischemic Stroke (AIS) Market Size is expected to witness high growth during the forecast period of 2023 to 2030. The global Acute Ischemic Stroke (AIS) Market is estimated to be valued at US$ 12 billion in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030.

Regional analysis shows that North America currently dominates due to developed healthcare infrastructure and rising incidence of strokes. However, Asia Pacific is poised to grow at the fastest pace due to improving healthcare standards, growing medical tourism and rising geriatric population.

Key players operating in the acute ischemic stroke (AIS) market are Medtronic, Stryker, Johnson & Johnson, Abbott, Terumo, Penumbra, Boston Scientific, and MicroPort Scientific.

Get More Insights Here

https://www.newsstatix.com/acute-ischemic-stroke-ais-market-size-share-growth-outlook-2023/